Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA
XTalks
JUNE 8, 2021
With a price tag of over $2.5 There are four main types of SMA — type 0 to IV — with type I being the most common and severe form of the disease. In England, five-month old baby Arthur became the country’s first SMA patient to receive the Zolgensma gene therapy last week through the National Health Service (NHS).
110 
Let's personalize your content